Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity

Immunotherapy of acute myeloid leukemia (AML) has been challenging because the lack of tumor-specific antigens results in “on-target, off-tumor” toxicity. To unlock the full potential of AML therapies, we used CRISPR-Cas9 to genetically ablate the myeloid protein CD33 from healthy donor hematopoieti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lydeard, John R., Lin, Michelle I., Ge, Huanying Gary, Halfond, Amanda, Wang, Shu, Jones, Mark B., Etchin, Julia, Angelini, Gabriella, Xavier-Ferrucio, Juliana, Lisle, Jessica, Salvadore, Kienan, Keschner, Yonina, Mager, Hannah, Scherer, Julian, Hu, Jianxin, Mukherjee, Siddhartha, Chakraborty, Tirtha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643325/
https://www.ncbi.nlm.nih.gov/pubmed/38027064
http://dx.doi.org/10.1016/j.omtm.2023.101135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643325/
https://www.ncbi.nlm.nih.gov/pubmed/38027064
http://dx.doi.org/10.1016/j.omtm.2023.101135

Ejemplares similares